Introduction
Although the presence of immune infiltrates of variable content in human solid tumors from different origins and different patients has long been established, the prognostic value of these components is still controversial. It is striking that Hanahan and Weinberg (2000) did not refer to immunity and inflammation in their statement about the hallmarks of cancers. However, accumulated data show that local inflammation strongly influences cancer development. Thus, following pioneering work of Coley (1893) on the antitumor effects of bacterial products, the creation of an acute local inflammation for the adjuvant treatment of superficial bladder cancer by BCG has become the state of the art for this malignancy (Herr and Morales, 2008) . Conversely, the deleterious effects of chronic inflammation in the outcome and progression of many tumors (gastric, colorectal, head and neck, so on) have for the most part been documented (Coussens and Werb, 2002) . During the same period, a series of publications, pioneered by that of Schreiber and colleagues, showed that, in mouse models, immune deficiencies were associated with the growth and aggressiveness of tumors (Dunn et al., 2004) . These data were reminiscent of clinical observations of higher incidences of cancer in immunodepressed individuals (Birkeland et al., 1995) . This body of evidence brought Schreiber to revisit the immune surveillance theory and to propose the 3E rules stating that the interaction of a tumor with the host immune system follows three steps: elimination, during which the immune reaction eradicates nascent tumor cells; equilibrium, during which the immune reaction controls tumor expansion and metastasis; and escape, as when some tumor cells have developed resistance to the host's immune system (Dunn et al., 2002) . Soon after, several publications analyzed the impacts of intratumoral lymphocyte infiltrates on clinical outcomes in large cohorts of human cancers and reported that a high adaptive immune infiltrate is a major prognostic factor in several solid cancers (ovarian, colorectal, lung, head and neck, melanoma, so on). Therefore, it is time to propose the immune reaction as a seventh hallmark of cancer, as proposed by Zitvogel et al. (2006) , and to integrate the analysis and quantification of immune infiltrates as a routine prognostic factor.
Evidence for variable immune infiltrates in human cancers that predict clinical outcome
Solid tumors are commonly infiltrated by immune cells (for example, T and B lymphocytes, natural killer (NK) cells, NK-T cells, dendritic cells (DCs), macrophages, neutrophils, eosinophils and mast cells). Epidemiological studies and experimental findings support a function for chronic inflammation in the promotion of cancers. The trigger for chronic inflammation might be microbial infections, the best example being helicobacter pylori for gastric cancer (Hohenberger and Gretschel, 2003) or mucosal lymphoma (Stolte et al., 2002) . Also involved are autoimmune and inflammatory diseases such as inflammatory bowel disease, Chron's disease or colitis for colon cancer or prostatitis for prostate cancer (Table 1 ). These observations have led to the use of nonsteroidal antiinflammatory drugs that inhibit the protumorigenic effects of cyclooxygenase-2 and its metabolite prostaglandin E2, for the prevention of colon cancer (Brown and DuBois, 2005; Castellone et al., 2005) . Macrophages, through the production of many factors that influence growth and survival of tumor cells, angiogenesis, cell invasion and chemotaxis or inhibition of T-cell responses, seem to be the predominant cells involved in this process. In a mouse model, de Visser et al. (2005) also implicated B lymphocytes as an initiator of chronic inflammation in an HPV 16-driven tumor. The functions of eosinophils and mast cells have also been debated (Nielsen et al., 1999) .
In contrast to infiltration of cells responsible for chronic inflammation, the presence of high numbers of lymphocytes, especially T cells, has been reported to be an indicator of good prognosis in many cancers such as melanoma, breast cancer, ovarian cancer, non-Hodgkin's lymphoma, head and neck cancer, non-small-cell lung cancer (NSCLC), esophageal cancer and urothelial carcinoma (Clemente et al., 1996; Schumacher et al., 2001; Zhang et al., 2003;  Table 2 ). One of the most studied human malignancies is colorectal cancer. The first reports on a beneficial effect of lymphocytic infiltration in colorectal cancer were published 20 to 30 years ago (House and Watt, 1979; Svennevig et al., 1984; Jass, 1986; Halvorsen and Seim, 1989) . They were confirmed then and again more recently by studies highlighting a prominent function for memory T cells (Page`s et al., 2005) and CD8 T cells (Naito et al., 1998) in predicting disease-free survival (DFS) and overall survival (OS).
It quickly became evident that a feature present in about 15% of colorectal tumors, that is, high level of microsatellite instability (MSI) resulting from DNA mismatch repair, was associated with high lymphocytic infiltration, particularly CD8 T cells. It is striking that MSI correlates with good prognosis (Popat et al., 2005) , and an attractive hypothesis is that this is due to mismatch repair deficiency creating multiple immunogenic peptides that become stimulants and targets of antitumor immune responses (Schwitalle et al., 2008) .
Because T-cell infiltration is not homogeneous in colonic tumors, attention has been focused on the predictive values of T cells in the center of the tumor (CT), in the invasive margin (IM) and in lymphoid islets located at the vicinity of the tumor. These analyses parallel similar ones in melanoma (Clemente et al., 1996) and in NSCLC . A comprehensive analysis of all components of the lymphocytic infiltrates in the context of their localization, their organization and their impact at various steps of tumor progression had not been completed in the early work. However, recent studies have shed some light on these issues and are presented and discussed here.
Correlation of high numbers of Th1 and cytotoxic memory T cells with the absence of metastatic invasion
The clinical outcome of a cancer is highly dependent on the capability of tumor cells to extravase the tumor through blood, lymphatic vessels or along neural routes, circulate in the body and establish in a distant organ, Immune infiltration in human tumors F Pagès et al forming a growing metastasis. During these steps, circulating tumor cells have to encounter the host's immune system and may, or may not, be arrested, destroyed or maintained in a dormant state (Teng et al., 2008) . We have thoroughly investigated the impact of the tumor-associated immune reaction in the primary tumor in the early stage of tumor metastasis, that is, the presence at the primary tumor of vascular emboli (VE), lymphatic invasion (LI) and perineural infiltration (PI), collectively referred as VELIPI.
We analyzed a cohort of 959 colorectal tumors from patients presenting with diverse tumor node metastasis (TNM) grading and from all colorectal locations (from right colon to rectum) with up to 15 years of clinical follow-up for the presence or absence of VELIPI (Page`s et al., 2005) . From this large cohort, we confirmed the pejorative prognostic value of the presence of VELIPI. Patients with no sign of metastatic invasion in their primary tumor (VELIPI-negative) had longer DFS and OS than patients with early signs of metastatic invasion (VELIPI-positive), based on Log-rank tests comparing patient groups (Po0.001).
We then analyzed tumor-infiltrating immune cells by gene expression profiling, flow cytometry and in situ immunohistochemistry and correlated the data with the VELIPI status of the tumor. After analyzing immuneassociated gene expression in 75 randomly selected tumors, we established that increased levels of genes associated with Th1 orientation (T-bet, IFNÀ) and effector function (CD8a, granzyme B (GZMB) and granulysin) were associated with the absence of signs of metastatic invasion (VELIPI-negative). In contrast, we found no correlation between the VELIPI status of the tumors and markers of inflammation (interleukin (IL)-8, vascular endothelial growth factor (VEGF), carcinoembryonic antigen-related cell adhesion molecule 1, matrix metalloproteinase-7, cyclooxygenase-2 and thrombospondin-1) or Th2 orientation (GATA-3). Next, we performed detailed analyses of immune infiltrates in 39 tumors using flow cytometry. Hierarchical clustering showed that markers of cell adhesion/migration (CD62 ligand, CCR7, CD103, CD49d and CXCR3), activation (HLA-DR, CD98, CD80, CD86 and CD134) and differentiation (CD45RO, CD45RA, CD27, CD28, CCR7 and CD127) were increased in VELIPI-negative tumors. Colorectal cancers without tumor emboli presented with significant increases in T-cell subpopulations from early memory (
, as assessed by flow cytometry of living cells extracted from 39 tumors.
By immunohistochemistry-based tissue Microarray analysis of 415 tumors, we determined the density of memory T-cell (CD45RO þ ) infiltration in tumors. Immunostainings were quantified using a dedicated image analysis workstation, providing a robust and reliable method to determine the density of immunostained cells. We confirmed that a high density of memory T cells (CD3 þ CD45RO þ cells) in the primary tumor correlated with the absence of early signs of metastatic invasion (VELIPI-positive).
Together, our results showed a positive correlation between a particular immune orientation-Th1 differentiation with cytotoxic and memory components-in tumors and the absence of microscopic evidence of early signs of tumor dissemination around the tumor and metastasis in distant organs. An attractive interpretation of these data is that even when a tumor has already reached a clinical stage, tumor-associated (expression of antigenic determinants, danger signals and so on) and inflammatory elements might convene to recruit an efficient, adaptive immune reaction that keeps tumor emboli in check. The natural history of a colorectal cancer could associate an immune escape at the tumor site with a degree of recognition of tumor emboli favoring an equilibrium phase after surgical removal of the tumor.
There was, however, a group of patients with high memory T-cell infiltrates in their primary tumor who presented with invaded lymph nodes and with distant metastasis at the time of diagnosis. These patients may represent examples of the escape phase proposed by Schreiber in which, by various mechanisms, tumors overwhelm immune system activity. For instance, angiogenesis mediated by VEGF is critical to the growth and malignant dissemination of solid tumors (Bergers and Benjamin, 2003) . Furthermore, under the pressure of antitumoral immune activity, selection and outgrowth of variant tumor cells with reduced immunogenicity could occur (Smyth et al., 2001; Dunn et al., 2004 Dunn et al., , 2006 . Thus, during cancer progression tumor cells may acquire immune tolerance mechanisms by generating complex immunosuppressive networks at the tumor site (Zou, 2005; Kim et al., 2006) , involving IL-10, transforming growth factor-b (TGF-b) or soluble IL-15 receptors (Badoual et al., 2008) , and T-cell-specific co-inhibitory molecules (CTLA-4 and PD-1) (Egen et al., 2002; Okazaki and Honjo, 2006) .
To understand whether putative tumor escape mechanisms had influenced the 'in situ' immune infiltrate in the primary tumor, we revisited our series of patients presenting with high T lymphocytes infiltration in the context of the presence or absence of metastasis. We analyzed by flow cytometry the 39 freshly resected tumors for various lymphocytic subpopulations. Metastatic patients had significantly decreased densities of CD8 T cells, whereas no difference was observed for CD4 cells or CD4 þ CD25 þ high T cells. When analyzing markers of memory T-cell differentiation, effector memory T cells (CD27
were almost absent from primary tumors of metastatic patients with high lymphocyte infiltration whereas there were no significant differences in early and late memory T cells (Camus et al., 2009;  Figure 1 ). In addition, we found by immunohistochemistry on a large cohort of 435 patients that high numbers of CD8 þ T cells among T cells correlated with lack of metastasis and protection against tumor recurrence (Camus et al., 2009) . Finally, analysis of gene expression in 103 patients revealed that, although associated with no prognostic effect by itself, high VEGF gene 
Coordinated adaptive immune response as the strongest prognostic factor in colorectal cancer
In addition to the total number of intratumoral T cells, the location of the lymphocytic infiltration within the tumor seems to be relevant in terms of prognosis. The impact of lymphoid islets with germinal center-like architecture found in the vicinity of the tumors is debated and will be discussed below. Most authors considered the immune infiltrate as reflecting tumor cell modifications such as MSI (Popat et al., 2005; Le Gouvello et al., 2008; Michel et al., 2008) , altered expression of major histocompatibility complex class I molecules (Bicknell et al., 1996) or production of chemokines (Balkwill, 2004) rather than representing a phenomenon that may control tumor dissemination. Immune infiltration was thus considered as an additional, rather weak, prognostic factor with no major impact on classical tumor, associated features, such as size (T), lymph node (N) or metastatic (M) invasion, oncogene mutation or VEGF production.
In colorectal tumors, as in other solid tumors, T cells are distributed in different tumoral areas: in the CT within the stroma and tumor glands, in IM and in lymphoid structures resembling germinal centers at the tumor periphery. The CT and IM of a total of 609 colorectal cancers of three independent series were investigated for the presence of total T lymphocytes (CD3 þ ), CD8 þ effector T cells and their associated cytotoxic molecules (GZMB) and memory T cells (CD45RO þ ) (Galon et al., 2006) . + CT/IM Lo. For each marker studied, a low density of cells in a single-tumor region markedly impaired the beneficial effect of the immune cell infiltrate at the tumor site. For example, the respective 5-year DFS and OS rates were 50.5 and 44.1% for patients with CD45RO
þ CT/IM-heterogeneous tumors (LoHi or HiLo). Thus, immune cell organization and densities within tumors strongly influenced prognosis of patients with colorectal cancer. This may indicate that the coordination of the immune reaction among tumor regions is required to mount an effective immune response but also that the immune compartments in each tumor region may control different tumor events (for example, tumor emboli, lymph node metastasis, distant metastases).
Prognosis of colorectal cancer is classically determined by the TNM staging system (Wittekind et al., 2002) , which relies on the depth of tumor invasion and the absence or presence of nodal and distant metastases. This system is used for estimating prognosis, planning treatment and measuring clinical outcome. The primary treatment modality for colon cancer is surgery. Patients presenting with Dukes' stage A or TNM stage I are subjected to curative surgery alone. Once the disease has spread to lymph nodes or to distant organ sites, chemotherapy is incorporated into treatment plans. Adjuvant chemotherapy is recommended for patients with nodal disease (Dukes' stage C or TNM stage III). Finally, Dukes' stage D or TNM stage-IV patients (distant metastasis) are treated by chemotherapy, with or without surgery. The TNM system, however, is far from being a fully reliable predictor, as 15-25% of patients with clinically localized cancer (Dukes' A and B or TNM stages I and II) will experience relapse, and up to 40% with Dukes' C (TNM stage III) will relapse regardless of treatment. Genetic and cellular markers of tumors, such as p53 expression, or MSI status of the tumor, have been proposed to predict relapse and patient survival, but have not reached a degree of confidence to be recommended for use in the clinic (Locker et al., 2006) .
The first condition required for a prognostic factor to be incorporated into staging is that it has a strong and reproducible impact on outcome, independent of tumor invasion. We stratified patients according to the UICC-TNM classification and evaluated whether the immune criteria could discriminate patient outcome at each step of cancer progression. Our investigation of three independent cohorts with univariate and multivariate analyses, conducted in multiple parallel manners, revealed that the natural adaptive immune reaction at the tumor site influenced clinical outcome at all stages of disease. Strikingly, the type, density and location of immune cells in colorectal cancers had a prognostic value that was superior to and independent of those of the UICC-TNM classification (for colorectal cancer, Immune infiltration in human tumors F Pagès et al stages I-III). A strong in situ immune reaction in both tumor regions correlated with a favorable prognosis, regardless of the local extent of the tumor and of invasion of regional lymph nodes (stages I-III). Conversely, a weak in situ immune reaction in both tumor regions correlated with a poor prognosis, even in patients with minimal tumor invasion. In multivariate analysis, after adjusting for tumor invasion (T stage), tumor differentiation and lymph node invasion (N stage), CD3-CT/IM density was the only independent parameter associated with OS. Moreover, in patients with coordinated high or low densities of immune markers in both tumor regions (HiHi or LoLo), the histopathological parameters were no longer associated with DFS and OS.
The fact that the local immune contexture (that is, density, phenotype, activation status and location of immune cells) appears to be the strongest prognostic factor for DFS and OS in colorectal cancer implies that immunological criteria should be of interest in clinical practice and added to tumor staging to improve the identification of high-risk patients who would benefit most from adjuvant therapy (Galon et al., 2007) . This approach should be extended to other cancers, particularly those where high numbers of infiltrating T cells have been associated with good prognosis.
Immune scoring in early stage colorectal cancers in clinical practice
As stated above, in early stage colorectal cancers in patients with no detectable lymph node or distant metastasis, surgery alone is the state of the art. However, a significant number of patients (20-25%) will have recurrence of the disease, indicating that they already had occult metastasis at the time of curative surgery. There is presently no marker to identify the group of patients who will have recurrence and might benefit from adjuvant therapy. We thus undertook a large study on 602 stage I and II patients from two independent cohorts to assess the importance of the intratumoral immune pattern in the surgically removed tumor to predict recurrence and OS in early stage colorectal patients.
Based on our previous observations (Galon et al., 2007 ) and our analysis of the genes whose coordinated expression was highly significantly enhanced in tumors with high memory T-cell infiltrates, we chose to count the latter, that is, the numbers of CD45RO þ and CD8 þ T cells. We found that 42% of the patients presented a high infiltration of CD8 þ and CD45RO þ cells in CT and IM regions of the tumors, whereas 4% had a low infiltration of these cells in both tumor regions. Strikingly, 46% of the patients presented with heterogeneity between the immune marker densities. We investigated whether a combined assessment of the memory and cytotoxic phenotypes could increase the accuracy of prediction of clinical outcome for the various patient groups.
As each marker in each tumor region positively influenced clinical outcome, we stratified the patients according to the total number of high densities (Hi) observed in the tumor (two markers assessed in two tumor regions, CT and IM). According to this criterion, 4, 10, 17, 27 and 42% of the patients presented with an immune score of (0)-Hi, (1)-Hi, (2)-Hi, (3)-Hi and (4)-Hi, respectively. Significant differences in DFS, diseasespecific survival and OS times among patients groups were determined by univariate analysis. Patients with high densities of CD45RO þ and CD8 þ cells in both tumor regions ((4)-Hi) were at low risk, with 5-year DFS and OS rates of 95.2 and 86.2%, respectively. In contrast, patients with low densities of CD45RO þ and CD8 þ cells in both tumor regions ((0)-Hi) were at high risk, with 5-year DFS and OS rates of 25 and 27.5%, respectively. Patients with an immune score of 1 or 2 high ((1)-Hi, (2)-Hi)) experienced a similarly poor postoperative outcome. Indeed, the cumulative 5-year DFS and OS rates of the grouped patients ((1-2)-Hi) were 56.4 and 61.6%, respectively ; Table 3 ).
These data indicate that a stratification of the patients based on the assessment of CD8 þ and CD45RO þ cell densities could be of interest in clinical practice. In multivariate analysis, the immune score and bowel perforation presentation remained the only independent prognostic factors, whereas T stage was no longer significant. Of note, perforation represented only 3.4% of the patients, and this percentage tends to decrease with earlier detection of colorectal cancer in recent years. In contrast, the immune score allowed classification of patients into groups with distinct clinical outcome in 73% of cases of the series. We thus propose that the intratumoral immune score, which appears to be a strong and reproducible prognostic factor independent of tumor invasion, be included in clinical practice.
T regulatory cells and prognosis
In a recent publication, Salama et al. (2009) reported an analysis of T-cell infiltrates in 967 colorectal tumors including 593 with stage II and 374 with stage III. They confirmed our previous findings that the density of CD45RO cells was lower in patients with early signs of metastasis, that is, vascular or perineural invasion. They Immune infiltration in human tumors F Pagès et al found that CD45RO and CD8 T cells correlate with MSI in the tumor. In a univariate analysis, high densities of intratumoral CD45RO, CD8 and strikingly FoxP3 þ cells correlated with good prognosis, whereas in multivariate analysis only the latter marker appeared to be associated with good prognosis in stage-II patients. High densities of FoxP3 cells in the normal mucosa adjacent to the tumor were somewhat deleterious. This study raises the possibility of FoxP3 þ cells (T regulatory cell, T reg) as a prognostic factor.
The question of the prognostic value of regulatory T cells in human cancers appears indeed to be a complex issue. The pioneering publication of Curiel et al. (2004) reported that the presence of high numbers of CD3
þ cells in malignant ascites of ovarian carcinoma correlated with tumor staging (that is, they were more abundant in individuals presenting with stages III and IV) and reduced survival. It was confirmed in other solid tumors, such as pancreatic ductal adenocarcinoma (Hiraoka et al., 2006b ) and hepatocarcinoma (Fu et al., 2007) . These findings gained large interest, because they supported the attractive hypothesis that the induction of T reg could be a major escape mechanism for human tumors and therefore could represent not only prognostic markers but, even more important, a target for immunotherapy.
However, data have accumulated suggesting that high numbers of intratumoral CD3 þ CD25 þ FoxP3 þ T cells are not always associated with poor prognosis but may in fact correlate with good prognosis. Such findings have been reported for follicular lymphoma and Hodgkin's lymphoma (Carreras et al., 2006; Tzankov et al., 2008) . In our own studies, we found that CD4
þ FoxP3 T-cell infiltration in head and neck cancer was associated with a better locoregional control of the tumor. Indeed, multivariate analysis showed that the only significant prognostic factors related to locoregional control were T stage and T reg infiltration of the tumor (Badoual et al., 2006) . In colorectal cancer, high densities of FoxP3 T cells were associated with MSI (Le Gouvello et al., 2008; Michel et al., 2008) , a feature usually associated with favorable prognosis. We found no association between FoxP3, CTLA-4, GITR, IL-10, TGF-b and the presence of intratumoral or distant metastasis. In their recent publication, Salama et al. (2009) reported that FoxP3 cells infiltration had even stronger prognostic significance than that of CD8 or CD45RO lymphocytes. Even in ovarian carcinoma, the absolute number of FoxP3 þ lymphocytes infiltrating the tumor epithelium was an independent prognostic factor for longer disease-specific survival in advanced stage and metastatic patients (Leffers et al., 2009 ). The issue is therefore still open and requires a more precise analysis of the subpopulation of cells expressing FoxP3 (CD4 or CD8, as proposed by Chaput et al. (2009) ), the relative proposition of T reg versus helper and cytotoxic T cells, their location in the center and the invasive margin of the tumor, the invaded lymph nodes and blood as well as functionality (Badoual et al., 2009) . Indeed, the facts that T reg can lose FoxP3 expression and change phenotype (Komatsu et al., 2009) , and normal T cells can acquire FoxP3 after multiple stimulations without becoming regulatory (Hoffmann et al., 2009) , add complexity to these analyses.
Adjacent tertiary lymphoid structures as the site of tumor-initiated immune reaction As described above, the density of tumor-infiltrating T lymphocytes with cytotoxic and memory phenotypes is highly predictive of favorable clinical outcome. A key issue is to understand where and how these cytotoxic T lymphocytes are activated and recruited before homing at the tumor site in the context of the complexity of the tumor ecosystem. We addressed this question in early stage lung cancer, which is still lacking reliable prognostic markers, and in an attempt to decipher the immune events that accompany the early steps of carcinogenesis. We investigated the presence and distribution of immune cell subsets by immunohistochemistry using a retrospective series of 74 successive patients diagnosed between 1998 and 2002 with early stage NSCLC (46 adenocarcinomas and 28 squamous cell carcinomas) and 5 nonpathological lung biopsies. In many tumors, immune cells are organized in tertiary lymphoid structures absent in the nontumoral lung. We therefore proposed to call these structures 'Ti-BALT' for tumor-induced bronchus-associated lymphoid tissues . Ti-BALT are composed of DC-Lamp/CD208
þ mature DC close to T-cell clusters, often adjacent to B-cell follicles characterized by the presence of Ki67 þ proliferating germinal center CD20 þ B cells and a network of CD21 þ follicular dendritic cells (FDCs).
We showed by univariate analysis that the density of mature DC, which home exclusively in the T-cell areas of Ti-BALT, was highly associated with a favorable clinical outcome (OS, DSS and DFS) þ T and T-bet þ cell compartments, which were dramatically decreased in DC-Lamp Low tumors, whereas the CD8 þ T-cell subset was less affected. Most CD4 þ T cells formed clusters with mature DC, in accordance with the observation that the decrease of the CD4 þ T-cell subset is strongly associated with a decrease in Ti-BALT density. The CD8 þ T cells were distributed in all tumor areas. Similarly to T cells, the density of tumor-infiltrating B cells was strongly increased in DC-Lamp High tumors. Thus, it is tempting to consider that Ti-BALT may reflect an ongoing immune response and that they may participate in antitumoral immunity.
Immune infiltration in human tumors
F Pagès et al Secondary lymphoid organs are traditionally considered important sites of immune activation. They contain B-cell follicles, separated T-cell areas and several subpopulations of DC and FDC. Their capacity to recruit naive and central memory lymphocytes and antigen-presenting cells as well as their architecture facilitates the generation of a robust adaptive immune response. Tertiary lymphoid structures develop in peripheral, nonlymphoid organs at sites of inflammation. Their architecture is similar to secondary lymphoid organs with T-and B-cell areas, DC subpopulations and high endothelial veinules. They can potentially arise in all inflamed tissues and do not appear in predictable sites. BALT have been described in the human fetus and infant lung (Gould and Isaacson, 1993) . Although they disappear in the normal adult lung (Tschernig and Pabst, 2000) , they develop in lung inflammatory diseases such as fibrosis, pneumonia, hypersensitivity pneumonitis, diffuse pan-bronchiolitis and in tobacco-induced inflammation. We found that Ti-BALT are adjacent to the tumor area in NSCLC, absent in the nontumoral tissue and their number is independent of the smoking history of the patients. The study of their relationship with the in situ inflammatory reaction is under investigation.
Tertiary lymphoid structures have been detected in peripheral lymphoid organs in a variety of autoimmune diseases and in graft rejection (Thaunat et al., 2008) . In this situation, their increase in size and number correlates with disease severity and local production of autoantibodies with an oligoclonal repertoire and hypersomatic mutations (Gause et al., 1995; Kotlan et al., 2003; RangelMoreno et al., 2006; Carragher et al., 2008; Humby et al., 2009) . On the contrary, the development of tertiary lymphoid structures, which occurs in nonlymphoid organs in several infectious diseases, may be beneficial and help to resolve the infection.
Whether tertiary lymphoid structures can initiate an immune response in a way similar to secondary lymphoid organs is still unclear in humans. Mouse experimental models provide accumulating evidence that adaptive immunity can be initiated independent of secondary lymphoid organs. For instance, splenectomized alymphoplastic mice can reject xenografts (Tesar et al., 2004) , clear viral infection with the development of primary and secondary immune responses (MoyronQuiroz et al., 2004 (MoyronQuiroz et al., , 2006 or mount an allergic airway inflammation after inhalation of allergens (Gajewska et al., 2001) . However, our results lead to the hypothesis that tertiary lymphoid structures adjacent to tumors could function as primary sites for the generation of antitumor adaptive immune reactions.
Concluding remarks: from tumor immune infiltrates to tumor immune contexture
Lymphocytic infiltration is a common feature of human cancers, including those that develop in immunoprivileged sites, such as the eye (Touitou et al., 2007) . Our data, in accordance with those of other groups, show that the type and functionality of the infiltrating lymphocytes is a major component of the host-tumor interactions, which strongly influences clinical outcome. Thus, high numbers of memory T cells with Th1 and cytotoxic orientation appear to be the strongest predictor of tumor recurrence after therapy. It is thus tempting to postulate that effector memory T cells prevent the escape of potentially metastatic cells from the primary tumor, thus diminishing the risk of relapse after tumor removal.
Interestingly, we found that the immune contexture (Galon et al., 2007; Pages et al., 2008) , as defined by the nature, the density, the functional orientation and the location of immune cells, is important to prediction of clinical outcome. Thus, high numbers of CD45RO þ T cells both in the CT and in the IM were required to give the best predictive values in CRC (Pages et al., 2008) . This phenomenon could even be observed at an early stage of tumor development, patients with high densities of CD45RO þ and CD8 þ cells in both tumor regions being at low risk, and patients with low densities of CD45RO þ and CD8 þ cells in both tumor regions at high risk . It is under investigation whether this reflects different functional roles of the lymphoid infiltrate to control lymph node invasion and metastasis and/or is associated with the in situ tumor heterogeneity.
It is generally assumed that antitumor immune responses are generated and controlled in the draining lymph nodes. However, our current observations in CRC and lung cancer suggest that this might also occur in the tumor. Strikingly, a strong correlation was found with the presence of innate cells, including DC and the group of CRC patients with high density of T cells and no detectable metastases, whereas the immune response was disorganized in patients with low T-cell numbers and detectable metastases (Camus et al., 2009) . Similarly, in early stage NSCLC, the density of mature DCs, which home exclusively in the T-cell areas of tertiary lymphoid structures, was highly associated with a favorable clinical outcome . These results strongly suggest that an efficient immune response may develop in the tumor after the early stage and may be required to control tumor invasion and metastasis. Hence, tumor-infiltrating lymphocytes are most likely not merely passive components of the tumor microenvironment; rather, they interact with each other in the tumor to mount and control the antitumor response. T cells may be primed and activated in tertiary lymphoid structures found in the vicinity of tumors, and they are probably induced by tumor-associated inflammation. In these structures, effector T cells may be primed and memory T cells could be educated to migrate to secondary lymphoid organs, such as lymph nodes, spleen, Peyer's patches, blood and so on, and thereby control disseminating cancer cells or migrate into nascent metastases.
Among lymphocyte populations, although the beneficial role of Th1 and CD8 þ T cells is established, that of T reg and B cells is still a matter of debate and needs In particular, what is needed is the analysis of the impact of their localization in the tumor, its vicinity or in the lymph node and of the cytokines or immunoglobulins they produce Badoual et al., 2009; Camus et al., 2009) .
A still-open question is whether T-cell infiltration is a prognostic factor or predicts response to chemotherapy, as suggested by a previous study (Halama et al., 2009 ). In our own experience, however, we found no modification of the immune contexture of colorectal tumors in patients who received preoperative, neoadjuvant chemotherapy . Therefore, we propose that memory T cell infiltration may be a prognostic marker that holds true in no matter what the treatment, because it was significant both in patients who underwent chemotherapy and in untreated patients. This does not, however, eliminate the possibility that immunemodifying chemotherapies that stimulate the immune system (Tesniere et al., 2008) or inhibit T reg (Ghiringhelli et al., 2007) may eventually modify the immune contexture of primary or metastatic tumors. Particular attention should be given to the analysis of the lymphocytic infiltrate in tumors resected after adjuvant chemo-or for immune therapies.
In any case, the analysis of the nature, the quantity, the location and the functionality of the immune infiltrates in human cancers becomes an essential step in establishing the prognosis of a human cancer. The molecular and immunohistochemical technologies that would allow the inclusion of such analyses in routine laboratory procedures are being refined and should soon be available. This will allow a comprehensive assessment of human tumors and a definitive answer regarding the inclusion of relevant tests in routine pathological examination. In parallel, careful studies on the nature of efficient immune reactions, the place where they are initiated, the cells and molecules involved, and their impact at different stages of the disease should provide new tools and goals for targeted therapies.
Conflict of interest
The authors declare no conflict of interest.
